Pacira BioSciences (PCRX) analyst forecast and price target
Analyst forecast
Consensus of 7 analyst ratings
Based on 3 analyst targets
Recent analyst ratings
| Firm | Action | Rating | Price target | Date |
|---|---|---|---|---|
| Needham | Maintained | Buy | $33.00 from $32.00 | Aug 5, 2026 |
| RBC Capital | Maintained | Sector Perform | $25.00 from $24.00 | Aug 5, 2026 |
| HC Wainwright & Co. | Maintained | Buy | $38.00 | Jul 1, 2026 |
| Needham | Maintained | Buy | $32.00 from $30.00 | May 1, 2026 |
| RBC Capital | Maintained | Sector Perform | $24.00 from $22.00 | May 1, 2026 |
| Barclays | Maintained | Equal-Weight | $25.00 from $27.00 | Mar 26, 2026 |
| Needham | Maintained | Buy | $30.00 | Jan 9, 2026 |
| HC Wainwright & Co. | Maintained | Buy | $38.00 | Jan 9, 2026 |
| Barclays | Initiated Coverage | Equal-Weight | $27.00 | Dec 9, 2025 |
| HC Wainwright & Co. | Initiated Coverage | Buy | $38.00 | Nov 17, 2025 |
| Truist Securities | Maintained | Buy | $28.00 from $30.00 | Nov 7, 2025 |
| Needham | Maintained | Buy | $30.00 from $32.00 | May 9, 2025 |
| HC Wainwright & Co. | Maintained | Buy | $65.00 from $48.00 | Apr 8, 2025 |
| Needham | Maintained | Buy | $32.00 | Apr 8, 2025 |
| HC Wainwright & Co. | Maintained | Buy | $70.00 from $57.00 | Feb 28, 2025 |
| Needham | Maintained | Buy | $32.00 from $30.00 | Feb 28, 2025 |
| Barclays | Maintained | Overweight | $24.00 from $17.00 | Feb 28, 2025 |
| Truist Securities | Upgraded | Sell → Hold | $25.00 from $8.00 | Jan 30, 2025 |
| RBC Capital | Maintained | Sector Perform | $18.00 | Jan 14, 2025 |
| Needham | Maintained | Buy | $30.00 from $22.00 | Jan 13, 2025 |
Frequently asked questions
What is the price target for PCRX stock?
The average 12-month analyst price target for Pacira BioSciences (PCRX) is $32.00, with a high estimate of $38.00 and a low of $25.00, across 3 analysts.
Is PCRX a buy, sell, or hold?
Analysts covering Pacira BioSciences currently average a Buy rating: 4 buy, 2 hold and 1 sell, from 7 analysts. Ratings reflect analyst opinion, not investment advice.
What upside do analysts see for PCRX?
The average price target of $32.00 implies 23.55% upside from the last price of $25.90.
What is the latest analyst rating on PCRX?
On Aug 5, 2026, Needham maintained Pacira BioSciences at Buy with a price target of $33.00.
Analyst ratings and price targets are the opinions of third-party research firms, not of Light Horse Securities. They are estimates about an uncertain future, are frequently wrong, and are neither a recommendation nor a prediction of actual results.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.